TITLE

Microvolt T-wave alternans testing in patients recently hospitalized with decompensated heart failure

AUTHOR(S)
Jackson, Colette E.; Myles, Rachel C.; McMurray, John J.V.
PUB. DATE
January 2014
SOURCE
European Journal of Heart Failure;Jan2014, Vol. 16 Issue 1, p113
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
No abstract available.
ACCESSION #
93427760

 

Related Articles

  • Is microvolt T-wave alternans testing suitable for patients recently hospitalized due to decompensated heart failure? Danilowicz-Szymanowicz, Ludmila; Molon, Giulio; Raczak, Grzegorz // European Journal of Heart Failure;Jan2014, Vol. 16 Issue 1, p112 

    No abstract available.

  • Search for HRV-parameters that detect a sympathetic shift in heart failure patients on β-blocker treatment. Yanru Zhang; de Peuter, Olav R.; Kamphuisen, Pieter W.; Karemaker, John M. // Frontiers in Physiology;Apr2014, Vol. 4, p1 

    Background: A sympathetic shift in heart rate variability (HRV) from high to lower frequencies may be an early signal of deterioration in a monitored patient. Most chronic heart failure (CHF) patients receive β-blockers. This tends to obscure HRV observation by increasing the fast variations....

  • New Cardiac Arrhythmia Syndrome Identified.  // Ascribe Newswire: Medicine;6/8/2004, p49 

    An international team led by researchers from Duke University Medical Center and the Howard Hughes Medical Institute have defined a previously undescribed inherited cardiac arrhythmia syndrome that can lead to sudden death and can strike young, seemingly healthy people. The researchers believe...

  • Chronic heart failure, chronotropic incompetence, and the effects of β blockade. Witte, K. K. A.; Cleland, J. G. F.; Clark, A. L. // Heart;Apr2006, Vol. 92 Issue 4, p481 

    Objective: To establish the prevalence of chronotropic incompetence in a cohort of patients with chronic heart failure (CHF) taking modern medications far heart failure, and whether this affected exercise capacity and predicted prognosis. Methods: Heart rate response to exercise was examined in...

  • Esmolol cardioplegia: the cellular mechanism of diastolic arrest. Fallouh, Hazem B.; Bardswell, Sonya C.; McLatchie, Linda M.; Shattock, Michael J.; Chambers, David J.; Kentish, Jonathan C. // Cardiovascular Research;Aug2010, Vol. 87 Issue 3, p552 

    Aims: Esmolol, an ultra-short-acting β-blocker, acts as a cardioplegic agent at millimolar concentrations. We investigated the mechanism by which esmolol induces diastolic ventricular arrest.

  • BETA-BLOCKER CONTINUATION VERSUS INTERRUPTION IN HEART FAILURE WORSENING.  // Ethnicity & Disease;Spring2007, Vol. 17 Issue 2, p405 

    The article offers information on the clinical trial conducted by the Assistance Publique Hopitaux de Paris which aims to demonstrate noninferiority of beta-blocker continuation compared to its interruption in patients with heart failure who are treated by a beta-blocker. Inclusion criteria...

  • Impact of elevated heart rate on clinical outcomes in patients with heart failure with reduced and preserved ejection fraction: a report from the CHART-2 Study. Takada, Tsuyoshi; Sakata, Yasuhiko; Miyata, Satoshi; Takahashi, Jun; Nochioka, Kotaro; Miura, Masanobu; Tadaki, Soichiro; Shimokawa, Hiroaki // European Journal of Heart Failure;Mar2014, Vol. 16 Issue 3, p309 

    Aims It is still controversial whether elevated baseline heart rate ( HR) is associated with higher mortality in patients with heart failure ( HF) with preserved ejection fraction ( HFpEF). We compared the impacts of baseline HR on mortality in patients with HFpEF and those with HF with reduced...

  • Women and the management of acute coronary syndrome.  // Canadian Journal of Physiology & Pharmacology;Sep2012, Vol. 90 Issue 9, p1151 

    Coronary heart disease (CHD) is the leading cause of morbidity and mortality in both men and women in the developed countries. Despite this fact, females are still under-represented in the majority of clinical trials. At the present time, only limited evidence is available with respect to the...

  • MERIT-HF mortality and morbidity data. Hjalmarson, Å.; Fagerberg, B. // Basic Research in Cardiology;Nov2000 Supplement 1, Vol. 95, pI98 

    This survival study was designed to address whether beta-1-blockade utilizing metoprolol CR/XL (controlled release/extended release) once daily added to standard therapy reduces mortality and morbidity in patients with decreased ejection fraction and symptoms of heart failure. Enrolled in a...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics